Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:2009:581939.
doi: 10.1155/2009/581939. Epub 2010 Jan 17.

Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma

Affiliations

Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma

Benjamin Piura et al. J Oncol. 2009.

Abstract

This review will focus on recent knowledge related to circulating autoantibodies (AAbs) to tumor-associated antigens (TAAs) in epithelial ovarian carcinoma. So far, the following TAAs have been identified to elicit circulating AAbs in epithelial ovarian carcinoma: p53, homeobox proteins (HOXA7, HOXB7), heat shock proteins (HSP-27, HSP-90), cathepsin D, cancer-testis antigens (NY-ESO-1/LAGE-1), MUC1, GIPC-1, IL-8, Ep-CAM, and S100A7. Since AAbs to TAAs have been identified in the circulation of patients with early-stage cancer, it has been speculated that the assessment of a panel of AAbs specific for epithelial ovarian carcinoma TAAs might hold great potential as a novel tool for early diagnosis of epithelial ovarian carcinoma.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. Journal of Proteome Research. 2008;7(4):1388–1394. - PubMed
    1. Gagnon A, Kim J-H, Schorge JO, et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clinical Cancer Research. 2008;14(3):764–771. - PubMed
    1. Koziol JA, Zhang J-Y, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clinical Cancer Research. 2003;9(14):5120–5126. - PubMed
    1. Zhang J-Y, Casiano CA, Peng X-X, Koziol JA, Chan EKL, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiology Biomarkers & Prevention. 2003;12(2):136–143. - PubMed
    1. Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Research. 2002;62(14):4041–4047. - PubMed